Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 912


Effect of body condition score and reuse of progesterone-releasing intravaginal devices on conception rate following timed artificial insemination in Nelore cows.

Pereira LL, Ferreira AP, Vale WG, Serique LR, Neves K, Morini AC, Monteiro BM, Minervino A.

Reprod Domest Anim. 2018 Feb 9. doi: 10.1111/rda.13150. [Epub ahead of print]


Profile of plasmatic progesterone on pregnancy, and the postpartum estrus of Dasyprocta prymnolopha (Rodentia: Dasyproctidae).

Guimarães DA, Ohashi OM, Singh M, Vale W.

Rev Biol Trop. 2016 Dec;64(4):1519-26.


CRFR1 activation protects against cytokine-induced β-cell death.

Blaabjerg L, Christensen GL, Matsumoto M, van der Meulen T, Huising MO, Billestrup N, Vale WW.

J Mol Endocrinol. 2014 Dec;53(3):417-27. doi: 10.1530/JME-14-0056. Epub 2014 Oct 16.


Corticotropin-releasing factor-binding protein (CRF-BP) inhibits CRF- and urotensin-I-mediated activation of CRF receptor-1 and -2 in common carp.

Manuel R, Metz JR, Flik G, Vale WW, Huising MO.

Gen Comp Endocrinol. 2014 Jun 1;202:69-75. doi: 10.1016/j.ygcen.2014.04.010. Epub 2014 Apr 24.


Expression and functional characterization of membrane-integrated mammalian corticotropin releasing factor receptors 1 and 2 in Escherichia coli.

Jappelli R, Perrin MH, Lewis KA, Vaughan JM, Tzitzilonis C, Rivier JE, Vale WW, Riek R.

PLoS One. 2014 Jan 17;9(1):e84013. doi: 10.1371/journal.pone.0084013. eCollection 2014.


CRF type 2 receptors mediate the metabolic effects of ghrelin in C2C12 cells.

Gershon E, Vale WW.

Obesity (Silver Spring). 2014 Feb;22(2):380-9. doi: 10.1002/oby.20535. Epub 2013 Sep 10.


Control of voltage-gated potassium channel Kv2.2 expression by pyruvate-isocitrate cycling regulates glucose-stimulated insulin secretion.

Jensen MV, Haldeman JM, Zhang H, Lu D, Huising MO, Vale WW, Hohmeier HE, Rosenberg P, Newgard CB.

J Biol Chem. 2013 Aug 9;288(32):23128-40. doi: 10.1074/jbc.M113.491654. Epub 2013 Jun 20.


Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products.

Vaughan JM, Donaldson CJ, Fischer WH, Perrin MH, Rivier JE, Sawchenko PE, Vale WW.

Endocrinology. 2013 Apr;154(4):1553-64. doi: 10.1210/en.2012-2011. Epub 2013 Mar 14.


Novel subunit-specific tonic GABA currents and differential effects of ethanol in the central amygdala of CRF receptor-1 reporter mice.

Herman MA, Contet C, Justice NJ, Vale W, Roberto M.

J Neurosci. 2013 Feb 20;33(8):3284-98. doi: 10.1523/JNEUROSCI.2490-12.2013.


Identification of polymorphisms in the osteopontin gene and their associations with certain semen production traits of water buffaloes in the Brazilian Amazon.

Rolim Filho ST, Ribeiro HF, de Camargo GM, Cardoso DF, Aspilcueta-Borquis RR, Tonhati H, Nunes KB, Vale WG, Barbosa EM, de Sousa KC.

Reprod Domest Anim. 2013 Oct;48(5):705-9. doi: 10.1111/rda.12144. Epub 2013 Jan 25.


Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala.

Flandreau EI, Bourke CH, Ressler KJ, Vale WW, Nemeroff CB, Owens MJ.

Psychoneuroendocrinology. 2013 Aug;38(8):1349-61. doi: 10.1016/j.psyneuen.2012.11.020. Epub 2012 Dec 23.


Urocortin 3 marks mature human primary and embryonic stem cell-derived pancreatic alpha and beta cells.

van der Meulen T, Xie R, Kelly OG, Vale WW, Sander M, Huising MO.

PLoS One. 2012;7(12):e52181. doi: 10.1371/journal.pone.0052181. Epub 2012 Dec 14.


Chronic activation of corticotropin-releasing factor type 2 receptors reveals a key role for 5-HT1A receptor responsiveness in mediating behavioral and serotonergic responses to stressful challenge.

Neufeld-Cohen A, Kelly PA, Paul ED, Carter RN, Skinner E, Olverman HJ, Vaughan JM, Issler O, Kuperman Y, Lowry CA, Vale WW, Seckl JR, Chen A, Jamieson PM.

Biol Psychiatry. 2012 Sep 15;72(6):437-47. doi: 10.1016/j.biopsych.2012.05.005. Epub 2012 Jun 15.


Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation.

Rissman RA, Staup MA, Lee AR, Justice NJ, Rice KC, Vale W, Sawchenko PE.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6277-82. doi: 10.1073/pnas.1203140109. Epub 2012 Mar 26.


Roles of activin family in pancreatic development and homeostasis.

Wiater E, Vale W.

Mol Cell Endocrinol. 2012 Aug 15;359(1-2):23-9. doi: 10.1016/j.mce.2012.02.015. Epub 2012 Mar 3. Review.


Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin.

Bilezikjian LM, Justice NJ, Blackler AN, Wiater E, Vale WW.

Mol Cell Endocrinol. 2012 Aug 15;359(1-2):43-52. doi: 10.1016/j.mce.2012.01.025. Epub 2012 Feb 4. Review.


Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis.

Gray PC, Vale W.

FEBS Lett. 2012 Jul 4;586(14):1836-45. doi: 10.1016/j.febslet.2012.01.051. Epub 2012 Feb 1. Review.


The Local Control of the Pituitary by Activin Signaling and Modulation.

Bilezikjian LM, Vale WW.

Open Neuroendocrinol J. 2011 Jan 1;4:90-101.


Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.

Ciarmela P, Islam MS, Reis FM, Gray PC, Bloise E, Petraglia F, Vale W, Castellucci M.

Hum Reprod Update. 2011 Nov-Dec;17(6):772-90. doi: 10.1093/humupd/dmr031. Epub 2011 Jul 25. Review.


Photo-cross-linkers incorporated into G-protein-coupled receptors in mammalian cells: a ligand comparison.

Coin I, Perrin MH, Vale WW, Wang L.

Angew Chem Int Ed Engl. 2011 Aug 22;50(35):8077-81. doi: 10.1002/anie.201102646. Epub 2011 Jul 12.


Impaired FSHbeta expression in the pituitaries of Foxl2 mutant animals.

Justice NJ, Blount AL, Pelosi E, Schlessinger D, Vale W, Bilezikjian LM.

Mol Endocrinol. 2011 Aug;25(8):1404-15. doi: 10.1210/me.2011-0093. Epub 2011 Jun 23.


Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet.

Jamieson PM, Cleasby ME, Kuperman Y, Morton NM, Kelly PA, Brownstein DG, Mustard KJ, Vaughan JM, Carter RN, Hahn CN, Hardie DG, Seckl JR, Chen A, Vale WW.

Diabetologia. 2011 Sep;54(9):2392-403. doi: 10.1007/s00125-011-2205-6. Epub 2011 Jun 11.


Systemic urocortin 2, but not urocortin 1 or stressin 1-A, suppresses feeding via CRF2 receptors without malaise and stress.

Fekete EM, Zhao Y, Szücs A, Sabino V, Cottone P, Rivier J, Vale WW, Koob GF, Zorrilla EP.

Br J Pharmacol. 2011 Dec;164(8):1959-75. doi: 10.1111/j.1476-5381.2011.01512.x.


Plasma concentration of progesterone and 17beta-estradiol of black-rumped agouti (Dasyprocta prymnolopha) during the estrous cycle.

Guimarães DA, Ramos RL, Ohashi OM, Garcia GW, Vale WG.

Rev Biol Trop. 2011 Mar;59(1):29-35.


Polymer-based cell-free expression of ligand-binding family B G-protein coupled receptors without detergents.

Klammt C, Perrin MH, Maslennikov I, Renault L, Krupa M, Kwiatkowski W, Stahlberg H, Vale W, Choe S.

Protein Sci. 2011 Jun;20(6):1030-41. doi: 10.1002/pro.636. Epub 2011 May 3.


Activin-A and myostatin response and steroid regulation in human myometrium: disruption of their signalling in uterine fibroid.

Ciarmela P, Bloise E, Gray PC, Carrarelli P, Islam MS, De Pascalis F, Severi FM, Vale W, Castellucci M, Petraglia F.

J Clin Endocrinol Metab. 2011 Mar;96(3):755-65. doi: 10.1210/jc.2010-0501. Epub 2010 Dec 22.


Glucocorticoids differentially regulate the expression of CRFR1 and CRFR2α in MIN6 insulinoma cells and rodent islets.

Huising MO, Pilbrow AP, Matsumoto M, van der Meulen T, Park H, Vaughan JM, Lee S, Vale WW.

Endocrinology. 2011 Jan;152(1):138-50. doi: 10.1210/en.2010-0791. Epub 2010 Nov 24.


Expression and regulation of corticotropin-releasing factor receptor type 2β in developing and mature mouse skeletal muscle.

Kuperman Y, Issler O, Vaughan J, Bilezikjian L, Vale W, Chen A.

Mol Endocrinol. 2011 Jan;25(1):157-69. doi: 10.1210/me.2010-0308. Epub 2010 Nov 17.


A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery.

Neufeld-Cohen A, Tsoory MM, Evans AK, Getselter D, Gil S, Lowry CA, Vale WW, Chen A.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19020-5. doi: 10.1073/pnas.1013761107. Epub 2010 Oct 11.


NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist.

Grace CR, Perrin MH, Gulyas J, Rivier JE, Vale WW, Riek R.

J Biol Chem. 2010 Dec 3;285(49):38580-9. doi: 10.1074/jbc.M110.121897. Epub 2010 Sep 15.


Expression of urocortin peptides in canine myocardium and plasma.

Veloso GF, Ohad DG, Francis AJ, Vaughan JM, Brownstein DG, Culshaw GJ, Vale WW, French AT, Jamieson PM.

Vet J. 2011 Jun;188(3):318-24. doi: 10.1016/j.tvjl.2010.05.019. Epub 2010 Jun 15.


Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failure.

Meili-Butz S, Bühler K, John D, Buser P, Vale WW, Peterson KL, Brink M, Dieterle T.

Eur J Heart Fail. 2010 Aug;12(8):797-804. doi: 10.1093/eurjhf/hfq054. Epub 2010 Apr 13.


Inhibin-A antagonizes TGFbeta2 signaling by down-regulating cell surface expression of the TGFbeta coreceptor betaglycan.

Looyenga BD, Wiater E, Vale W, Hammer GD.

Mol Endocrinol. 2010 Mar;24(3):608-20. doi: 10.1210/me.2008-0374. Epub 2010 Feb 16.


CRFR1 is expressed on pancreatic beta cells, promotes beta cell proliferation, and potentiates insulin secretion in a glucose-dependent manner.

Huising MO, van der Meulen T, Vaughan JM, Matsumoto M, Donaldson CJ, Park H, Billestrup N, Vale WW.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):912-7. doi: 10.1073/pnas.0913610107. Epub 2009 Dec 22.


Injection of Urocortin 3 into the ventromedial hypothalamus modulates feeding, blood glucose levels, and hypothalamic POMC gene expression but not the HPA axis.

Chen P, Vaughan J, Donaldson C, Vale W, Li C.

Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E337-45. doi: 10.1152/ajpendo.00402.2009. Epub 2009 Dec 1.


Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits.

Neufeld-Cohen A, Evans AK, Getselter D, Spyroglou A, Hill A, Gil S, Tsoory M, Beuschlein F, Lowry CA, Vale W, Chen A.

Mol Psychiatry. 2010 Apr;15(4):426-41, 339. doi: 10.1038/mp.2009.115. Epub 2009 Nov 3. Erratum in: Mol Psychiatry. 2010 Apr;15(4):442.


Corticotropin-releasing factor (CRF) sensitization of ethanol withdrawal-induced anxiety-like behavior is brain site specific and mediated by CRF-1 receptors: relation to stress-induced sensitization.

Huang MM, Overstreet DH, Knapp DJ, Angel R, Wills TA, Navarro M, Rivier J, Vale W, Breese GR.

J Pharmacol Exp Ther. 2010 Jan;332(1):298-307. doi: 10.1124/jpet.109.159186. Epub 2009 Oct 20.


Functional amyloids as natural storage of peptide hormones in pituitary secretory granules.

Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, Singru PS, Nilsson KP, Simon R, Schubert D, Eisenberg D, Rivier J, Sawchenko P, Vale W, Riek R.

Science. 2009 Jul 17;325(5938):328-32. doi: 10.1126/science.1173155. Epub 2009 Jun 18.


Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.

Kelber JA, Panopoulos AD, Shani G, Booker EC, Belmonte JC, Vale WW, Gray PC.

Oncogene. 2009 Jun 18;28(24):2324-36. doi: 10.1038/onc.2009.97. Epub 2009 May 4.


Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes.

Wiater E, Lewis KA, Donaldson C, Vaughan J, Bilezikjian L, Vale W.

Mol Endocrinol. 2009 Jul;23(7):1033-42. doi: 10.1210/me.2009-0021. Epub 2009 Apr 16.


Social defeat stress activates medial amygdala cells that express type 2 corticotropin-releasing factor receptor mRNA.

Fekete EM, Zhao Y, Li C, Sabino V, Vale WW, Zorrilla EP.

Neuroscience. 2009 Aug 4;162(1):5-13. doi: 10.1016/j.neuroscience.2009.03.078. Epub 2009 Apr 7.


A novel corticotropin-releasing factor receptor splice variant exhibits dominant negative activity: a putative link to stress-induced heart disease.

Sztainberg Y, Kuperman Y, Issler O, Gil S, Vaughan J, Rivier J, Vale W, Chen A.

FASEB J. 2009 Jul;23(7):2186-96. doi: 10.1096/fj.08-128066. Epub 2009 Feb 26.


Immediate and sustained blood pressure lowering by urocortin 2: a novel approach to antihypertensive therapy?

Dieterle T, Meili-Butz S, Bühler K, Morandi C, John D, Buser PT, Rivier J, Vale WW, Peterson KL, Brink M.

Hypertension. 2009 Apr;53(4):739-44. doi: 10.1161/HYPERTENSIONAHA.108.125211. Epub 2009 Feb 9.


FoxL2 and Smad3 coordinately regulate follistatin gene transcription.

Blount AL, Schmidt K, Justice NJ, Vale WW, Fischer WH, Bilezikjian LM.

J Biol Chem. 2009 Mar 20;284(12):7631-45. doi: 10.1074/jbc.M806676200. Epub 2008 Dec 23.


Presence, actions, and regulation of myostatin in rat uterus and myometrial cells.

Ciarmela P, Wiater E, Smith SM, Vale W.

Endocrinology. 2009 Feb;150(2):906-14. doi: 10.1210/en.2008-0880. Epub 2008 Oct 9.


Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation.

Hao Z, Huang Y, Cleman J, Jovin IS, Vale WW, Bale TL, Giordano FJ.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3939-44. doi: 10.1073/pnas.0712366105. Epub 2008 Feb 28.


Activin-A in myometrium: characterization of the actions on myometrial cells.

Ciarmela P, Wiater E, Vale W.

Endocrinology. 2008 May;149(5):2506-16. doi: 10.1210/en.2007-0692. Epub 2008 Jan 31.


Residues of corticotropin releasing factor-binding protein (CRF-BP) that selectively abrogate binding to CRF but not to urocortin 1.

Huising MO, Vaughan JM, Shah SH, Grillot KL, Donaldson CJ, Rivier J, Flik G, Vale WW.

J Biol Chem. 2008 Apr 4;283(14):8902-12. doi: 10.1074/jbc.M709904200. Epub 2008 Jan 29.


A Smad-binding element in intron 1 participates in activin-dependent regulation of the follistatin gene.

Blount AL, Vaughan JM, Vale WW, Bilezikjian LM.

J Biol Chem. 2008 Mar 14;283(11):7016-26. doi: 10.1074/jbc.M709502200. Epub 2008 Jan 8.

Supplemental Content

Support Center